Aktis Oncology, Inc.
AKTS
$21.62
-$0.03-0.14%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/14/2026
-
MarketBeat
1/23/2026
-
MarketBeat
1/22/2026
-
MarketBeat
1/21/2026
-
MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Friday, January 9, 2026
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Jan 4 and 8 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
--
60-Day Total Return
--
90-Day Total Return
--
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
617-461-4023
Address
17 Drydock Avenue
Boston, MA 02210
Boston, MA 02210
Country
Year Founded
Business Description
Sector
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein...
more